Literature DB >> 18668342

What we know that could influence future treatment of phenylketonuria.

C N Sarkissian1, A Gámez, C R Scriver.   

Abstract

Phenylketonuria (PKU), a Mendelian autosomal recessive phenotype (OMIM 261600), is an inborn error of metabolism that can result in impaired postnatal cognitive development. The phenotypic outcome is multifactorial in origin, based both in nature, the mutations in the gene encoding the L-phenylalanine hydroxylase enzyme, and nurture, the nutritional experience introducing L-phenylalanine into the diet. The PKU story contains many messages including a framework to appreciate the complexity of this disease where phenotype reflects both locus-specific and genomic components. This knowledge is now being applied in the development of patient-specific therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18668342     DOI: 10.1007/s10545-008-0917-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  74 in total

1.  Malignant hyperphenylalaninaemia--current status (June 1977).

Authors:  D M Danks; K Bartholomé; B E Clayton; H Curtius; H Gröbe; S Kaufman; R Leeming; W Pfleiderer; H Rembold; F Rey
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Systems biology. Life's complexity pyramid.

Authors:  Zoltán N Oltvai; Albert-László Barabási
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

3.  THE STRUCTURE OF THE PHENYLALANINE-HYDROXYLATION COFACTOR.

Authors:  S KAUFMAN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-12       Impact factor: 11.205

Review 4.  Protein therapeutics: a summary and pharmacological classification.

Authors:  Benjamin Leader; Quentin J Baca; David E Golan
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

5.  Correction of phenylketonuria after liver transplantation in a child with cirrhosis.

Authors:  P Vajro; P Striscìuglio; D Houssin; G Huault; J Laurent; F Alvarez; O Bernard
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

6.  Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions.

Authors:  L R Desviat; B Pérez; A Gámez; A Sánchez; M J García; M Martínez-Pardo; C Marchante; D Bóveda; A Baldellou; J Arena; P Sanjurjo; A Fernández; M L Cabello; M Ugarte
Journal:  Eur J Hum Genet       Date:  1999-04       Impact factor: 4.246

7.  Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

Authors:  C O Harding; M B Gillingham; K Hamman; H Clark; E Goebel-Daghighi; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

8.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

Authors:  E Kayaalp; E Treacy; P J Waters; S Byck; P Nowacki; C R Scriver
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

Review 9.  Gene therapy for phenylketonuria.

Authors:  R C Eisensmith; S L Woo
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 10.  Treatment of phenylalanine hydroxylase deficiency.

Authors:  I Smith
Journal:  Acta Paediatr Suppl       Date:  1994-12
View more
  10 in total

Review 1.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

Review 2.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

3.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

4.  Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.

Authors:  H J Vernon; C B Koerner; M R Johnson; A Bergner; A Hamosh
Journal:  Mol Genet Metab       Date:  2010-04-03       Impact factor: 4.797

5.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

Review 6.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

7.  Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.

Authors:  Alexandre Rebuffat; Cary O Harding; Zhaobing Ding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

8.  Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Authors:  Erin L MacLeod; Sally T Gleason; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2009-08-08       Impact factor: 4.797

9.  5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.

Authors:  Diego Andolina; David Conversi; Simona Cabib; Antonio Trabalza; Rossella Ventura; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  Int J Neuropsychopharmacol       Date:  2010-11-01       Impact factor: 5.176

10.  Intellectual and Developmental Status in Children With Hyperphenylalaninemia and PKU Who Were Screened in a National Program.

Authors:  Parisa Aghasi; Arya Setoodeh; Azadeh Sayarifard; Maryam Rashidiyan; Fatemeh Sayarifard; Ali Rabbani; Javad Mahmoudi-Gharaei
Journal:  Iran J Pediatr       Date:  2015-12-23       Impact factor: 0.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.